Standout Papers

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation 2024 202667
  1. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (2024)
    Surya P. Bhatt, Klaus F. Rabe et al. New England Journal of Medicine
  2. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials (2024)
    Marcus Maurer, Thomas B. Casale et al. Journal of Allergy and Clinical Immunology

Immediate Impact

10 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Remibrutinib in Chronic Spontaneous Urticaria
2025 Standout
STING orchestrates the neuronal inflammatory stress response in multiple sclerosis
2024 Standout
2 intermediate papers

Works of Déborah Bauer being referenced

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
2024 Standout
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Déborah Bauer 526 556 384 436 34 1.8k
Philipp von Rosenstiel 254 1296 844 301 53 2.4k
Carl Bjartmar 281 1401 674 580 30 2.8k
Gilles Edan 310 868 171 137 66 1.8k
Jack C. Sipe 139 580 299 399 31 1.7k
Elena Fumagalli 328 168 442 321 103 2.6k
Judith C. Fleming 192 485 385 222 19 1.6k
Marco Rizzo 181 729 866 647 37 2.3k
Djordje Gverić 136 700 592 260 27 2.4k
Jorge E. Ortega 322 288 320 299 42 1.9k
Gilmore O’Neill 244 934 450 128 27 2.0k

All Works

Loading papers...

Rankless by CCL
2026